Tan J; ROSCO coauthors. Updating the diagnosis, classification and assessment of rosacea by effacement of subtypes: reply from the author. Br J Dermatol. 2017 Aug;177(2):598-599.
Tan J., Schofer H., Araviiskaia E., Audibert F, Kerrouche N, Berg M; Prevalence of rosacea in the general population of Germany and Russia the RISE study. JEADV, 2016 Mar;30(3):428-34.
Elewsky B, Draelos Z, Dreno B. Rosacea global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. JEADV 2011;25:188-200.
Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004 Sep;51(3):327-41.
Powell FC. Rosacea. N Engl J Med 2005; 352: 793 803. 2 Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett 2007; 12: 1 5, 9.
Garnis-Jones S. Psychological aspects of rosacea. J Cutan Med Surg 1998; 2 (Suppl. 4): 4 9.
Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989; 69: 419 423.
Самцов А.В. Акне и акнеиформные дерматозы. Монография М.: OOO «ЮТКОМ», 2009. 208 с.: ил.
Powell F.C, Rosacea. N. Engel J. Med. 2005; 352: 793-803
Руководство по дерматокосметологии / Под ред. Аравийской Е.Р.и Соколовского Е.В.. CПб.: ООО «Издательство Фолиант:», 2008. 632 с.
Lacey N, Delaney S, Kavanagh K et al. Mite related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007;157: 474-481.
Frank S et al. Regulation of VEGF expression in cultured keratrinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 1995; 270: 12607 12613
Gomaa A, Yaar M, Eyada M et al. Lymphahgiogenesis and angiogenesis in non-phymatosis rosacea. J Cutan Pathol 2007;34:748-753.
Whitfeld M, Gunasingam N, Leow L et al. Staphylococcus epidermidis: a possible role in thye pustules of rosacea. J Am Acad Dermatol 2011;64:49-59.
Moran A.P.Patogenic properties of Helicobakter pylori. Scan.J. Gastroenterol. -1996;. 31; 215; 22-31.
Wolf R. Acne rosacea and Helycobacter pylori betrothed .Int.J.Dermatol. 1996;35;4;: 302 303.
Rebora A., Drago F., Parodi A. May Helicobacter pylori be important for dermatologist. Dermatology 1995; 191; 6 - 8.
Diaz C., Oсallaghan C.J., Khan A., Ilchyshyn A. Rosacea: a cutaneous marker of Helicjbacter pylori infection? Result of a pylot studi. Acta Derm. Venerol. 2003; 4: 282 286
Bamford J. Rosacea: current thouthts on origin. Semin Cutan Med Surg 2001;20:199-206. Zuber T.Rosacea.Prim Care 2000;27:309-318.
Wilkin J., Dahl M., Detmar M., Drake L. et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584-7.
Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Schäfer G. Defining treatment success in rosacea as “clear” may provide multiple patient benefit: results of pooled analysis. Journal of Dermatological Treatment, 2017;28 (5):469-474.
van Zuuren EJ, Graber MA, Hollis S et al. Interventions for rosacea Cochrane Database Syst Rev 2005; Jul 20: CD003262.
Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013 Mar;91(3 Suppl):1-8
Sneddon I. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649 653.
Thilboutot D. Efficasy and safety of subantimicrobial-dose doxycycline for the threatment of rosacea J. Am. Acad. Dermatol. 2005; 52: 3-P 17.
Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102: 443 445.
Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211 1212.
Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013 Aug;54(3):157-62.
Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010 Jul;8(7):505-15.
Hofer T. Continuous ‘microdose’ isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol 2004; 29: 204 205.
Gollnick H. Optimal Isotretinoin Dosing for Rosacea, 18th Congress of the European Academy of Dermatology and Venereology, Berlin 2009.
Gollnick H.P., Bettoli V., Lambert J., Araviiskaia E., et al. Aconsensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1480-90.
Панкина Е.С. Нарушения микроциркуляции кожи лица при розацеа и методы их коррекции. Автореф канд дис СПб,2008, 20 c.
Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Liu H, Jacovella J. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. JDD, 2014;13(3):316-323.
Ventre E, Rozières A, Lenief V, Albert F, Rossio P, Laoubi L, Dombrowicz D, Staels B, Ulmann L, Julia V, Vial E, Jomard A, Hacini-Rachinel F, Nicolas JF, Vocanson M. Topical ivermectin improves allergic skin inflammation. Allergy. 2017 Aug;72(8):1212-1221.
Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J; Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial.Br J Dermatol. 2015 Apr;172(4):1103-10.
Taieb A, Khemis A, Ruzicka T, Barańska-Rybak W, Berth-Jones J, Schauber J, Briantais P, Jacovella J, Passeron T; Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016 May;30(5):829-36.